Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: An example of selective anti-TSH-receptor immune response by Rotondi, Mario et al.
September 2017 | Volume 8 | Article 2541
Review
published: 28 September 2017
doi: 10.3389/fendo.2017.00254
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Cesidio Giuliani, 
Università degli Studi 
“G. d’Annunzio” Chieti – 
Pescara, Italy
Reviewed by: 
Motoyasu Saji, 
The Ohio State University 
Columbus, United States  
Amanda Katherine Huber, 
University of Michigan, 
United States
*Correspondence:
Luca Chiovato  
luca.chiovato@icsmaugeri.it
Specialty section: 
This article was submitted 
to Thyroid Endocrinology, 
a section of the journal 
Frontiers in Endocrinology
Received: 26 July 2017
Accepted: 15 September 2017
Published: 28 September 2017
Citation: 
Rotondi M, Molteni M, Leporati P, 
Capelli V, Marinò M and Chiovato L 
(2017) Autoimmune Thyroid 
Diseases in Patients Treated 
with Alemtuzumab for Multiple 
Sclerosis: An Example of 
Selective Anti-TSH-Receptor 
Immune Response. 
Front. Endocrinol. 8:254. 
doi: 10.3389/fendo.2017.00254
Autoimmune Thyroid Diseases in 
Patients Treated with Alemtuzumab 
for Multiple Sclerosis: An example  
of Selective Anti-TSH-Receptor 
immune Response
Mario Rotondi1, Martina Molteni1, Paola Leporati1, Valentina Capelli 2, Michele Marinò3  
and Luca Chiovato1*
1 Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, ICS-Maugeri IRCCS,  University of Pavia,  
Pavia, Italy, 2 Department of Internal Medicine and Therapeutics, and Department of Medical and Surgical Sciences, 
University of Pavia, Pavia, Italy, 3 Endocrinology Unit I, Department of Clinical and Experimental Medicine, University of Pisa, 
University Hospital of Pisa, Pisa, Italy
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the 
treatment of active relapsing-remitting multiple sclerosis (MS). Alemtuzumab induces 
a rapid and prolonged depletion of lymphocytes from the circulation, which results in 
a profound immuno-suppression status followed by an immune reconstitution phase. 
Secondary to reconstitution autoimmune diseases represent the most common side 
effect of Alemtuzumab treatment. Among them, Graves’ disease (GD) is the most 
frequent one with an estimated prevalence ranging from 16.7 to 41.0% of MS patients 
receiving Alemtuzumab. Thyrotropin (TSH) receptor (R)-reactive B  cells are typically 
observed in GD and eventually present this autoantigen to T-cells, which, in turn, 
secrete several pro-inflammatory cytokines and chemokines. Given that reconstitution 
autoimmunity is more frequently characterized by autoantibody-mediated diseases 
rather than by destructive Th1-mediated disorders, it is not surprising that GD is the 
most commonly reported side effect of Alemtuzumab treatment in patients with MS. 
On the other hand, immune reconstitution GD was not observed in a large series of 
patients with rheumatoid arthritis treated with Alemtuzumab. This negative finding 
supports the view that patients with MS are intrinsically more at risk for developing 
Alemtuzumab-related thyroid dysfunctions and in particular of GD. From a clinical 
point of view, Alemtuzumab-induced GD is characterized by a surprisingly high rate of 
remission, both spontaneous and after antithyroid drugs, as well as by a spontaneous 
shift to hypothyroidism, which is supposed to result from a change from stimulating 
to blocking TSH-receptor antibodies. These immune and clinical peculiarities support 
the concept that antithyroid drugs should be the first-line treatment in Alemtuzumab-
induced Graves’ hyperthyroidism.
Keywords: Graves’ disease, Alemtuzumab, multiple sclerosis, autoimmune thyroid disease, reconstitution 
syndrome
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ALeMTUZUMAB AS AN 
iMMUNOMODULATiNG DRUG
Alemtuzumab is a humanized monoclonal antibody that has been 
approved for the treatment of active relapsing-remitting (RR) 
multiple sclerosis (MS) (1, 2). As a main pharmacologic action, 
Alemtuzumab targets the cell-surface antigen CD52. CD52 is a 
cell-surface glycoprotein with a still poorly understood function. 
CD52 is expressed on the surface of more than 95% T and B cells, 
of monocytes and of some dendritic cells, and, although to a lesser 
extent, even on natural killer cells and other leukocytes (3). The 
binding of Alemtuzumab to lymphocytes induces cellular lysis lead-
ing to their rapid and prolonged depletion from the circulation (4).
The acute immuno-suppressive effect of Alemtuzumab is 
followed by the homeostatic reconstitution of immune cells. 
Typically, monocytes and B cells recover first, followed by CD4+ 
T  cells. Changes in lymphocyte subsets result in an increased 
number of T  regulatory (Treg) cells and of memory T and 
B lymphocytes; an increased production of anti-inflammatory 
cytokines also occurs (5). These events produce a profound rebal-
ance of the immune system (6, 7).
Circulating lymphocytes disappear within a few minutes 
after the administration of Alentuzumab. B cells recover within 
3  months and a dominance of mature naïve cells (CD19+ 
CD23+ CD27−) over the memory B cells occurs. CD4+ T cell 
counts are restored after 35 months, while CD8+ T cell counts 
are restored after 20  months. The faster recovery of the latter 
subset of T cells might be related to the development of autoim-
mune diseases (8). For at least 9 months after the administration 
of Alemtuzumab, most circulating T  cells are represented by 
effector memory CD4+ and CD8+ cells. Baker et  al. recently 
described the kinetics of lymphocyte subset reconstitution after 
Alemtuzumab (9). After depletion, B  cells repopulated much 
more rapidly than T cells in general and Treg in particular (9). 
In this scenario, the reconstitution of B cells without adequate 
regulatory control by T cells may explain the high prevalence of 
post-Alentuzumab autoimmunity (9, 10).
Alentuzumab-induced lymphocytopenia is followed by the 
homeostatic growth of T cells, which is stimulated by the T cell 
receptor–self peptide complex. The process results in the appear-
ance of an oligoclonal cell population, which tends to autoreactiv-
ity. New T cell populations have typical aspects of memory T cells, 
such as lower dependency to co-stimulation, need for lower 
antigen doses than naïve cells, and faster secrection of inflam-
matory cytokines when re-stimulated (6–8). The above described 
immune derangements lead to a reduced self-tolerance. In most 
patients, the proliferation of regulatory lymphocytes is unable to 
prevent autoimmune deseases, possibly because T cells undergo 
a faster homeostatic growth, which increases their resistance 
to regulation (8). Patients who developed autoimmunity after 
Alentuzumab treatment also show high basal levels of IL-21, 
a cytokine which increases the growth of auto-reactive T cells. 
In general, the cytokine expression is skewed to the Th2 profile, 
in agreement with the high B cell counts (11, 12).
Innate immunity is not affected, and no clinically relevant 
infection appears after Alentuzumab treatment. This can be due 
to the maintenance/growth of memory T cells.
The above described immunomodulating actions of Alem-
tuzumab are responsible for its favorable effects in patients 
with RRMS (13), but also explain the high prevalence of 
Alemtuzumab-induced autoimmunity. The latter event received 
great concern and clinical trials aimed at evaluating potential 
preventive measures were designed (CAM-THY) (8, 14, 15).
MS AND THYROiD DiSeASeS
Multiple sclerosis is a human chronic inflammatory disease of 
the central nervous system supposed to be a Th1/Th17 type 
cell-mediated autoimmune disorder (16, 17). Studies aimed at 
evaluating whether there is an increased prevalence of autoim-
mune thyroid diseases (AITDs) in patients with MS as compared 
with healthy controls reported conflicting results. While early 
studies found an increased prevalence of AITD in patients with 
MS, more recent surveys reported rates which are consistent 
with the AITD prevalence in the general population (18–21). 
According to more recent views, an increased prevalence of 
AITD would be observed in family members of patients with MS 
(22). This is a rather intriguing and yet to be a fully elucidated 
observation (23, 24).
In addition to studies aimed at evaluating the prevalence 
of AITD in naive patients with MS, the occurrence of AITD, 
as a side effect of immunomodulatory treatments for MS, was 
extensively reported (25–27). At present, we know that treat-
ment with interferon-β (IFN-β) increases the risk for worsening 
and/or de novo appearance of both thyroid autoimmunity and 
dysfunction. On the other hand, thyroid side effects were not 
observed following glatiramer acetate (GA) therapy, even in 
large series of patients with MS who were longitudinally fol-
lowed for more than 10 years (11, 28, 29).
Specifically designed head-to-head clinical studies demon-
strated a similar efficacy of IFN-β and GA, as assessed by their 
ability to prevent clinical relapses and disease progression in 
patients with MS (12). However, more effective pharmacologic 
agents are now available. Among them, Alemtuzumab is cur-
rently regarded as an effective second-line treatment in patients 
with highly active RRMS (1, 2, 13).
TSH-ReCePTOR (TSH-R) AS A MAJOR 
AUTOANTiGeN iN GRAveS’ DiSeASe
Graves’ disease (GD), also referred to as toxic diffuse goiter, is 
commonly regarded as an autoimmune organ-specific disease 
(30–32). The presence of extra-thyroid manifestations, such 
as Graves’ orbitopathy and pretibial myxedema, apparently 
contradicts this classification, which is, however, justified by the 
TSH-R being a common antigen shared by the thyroid gland and 
by extra-thyroid tissues (31). The TSH-R, a G-protein coupled 
receptor with seven transmembrane-spanning domains and a 
large extracellular portion, is expressed primarily on the surface 
of thyroid follicular cells, but it is also present in adipocytes, 
fibroblast, bone cells, and other sites including the heart (33). 
TSH-R Antiboides (TRAb) encompass stimulating, blocking, 
and neutral antibodies. In patiens with GD, TRAb mainly have 
TABLe 1 | Thyroid dysfunction during Alemtuzumab treatment in patients with 
multiple sclerosis (MS).
Patients and dysfunctions (%)
Patients with thyroid dysfunction in the 216 patients 
cohort
34
•	 Graves’ hyperthyroidism
•	 Hypothyroidism
•	 Destructive thyroiditis
22.4
7.4
4.2
Type of dysfunction in the 73 affected patients
•	 Graves’ hyperthyroidism
•	 Hypothyroidism
•	 Destructive thryoiditis
•	 Unknown
65.8
20.5
10.3
1.4
Number of events of thyroid dysfunction between the 102 
recorded events
•	 Single
•	 Multiple
70.0
30.0
Type of event among the 102 recorded events
•	 Graves’ hyperthyroidism
 ⚬ Overt
 ⚬ Subclinical
•	 Hypothyroidism
•	 Destructive thryoiditis
•	 Unknown
•	 Graves’ orbitophaty
58.8
81.7
18.3
29.4
9.8
2.0
6.0
Results of the CAMMS223 study as categorized by Daniels et al. (42).
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thyroid-stimulating activity (TSAb), which results in hyper-
thyroidism and goiter formation, TSAb bind only the naturally 
conformed TSH-R and induce cyclic AMP generation, thyroid 
cell proliferation, and thyroid hormone synthesis and secretion 
(34, 35). More rarely, and less functionally dominant, TRAb 
with thyroid blocking activity have been described in patients 
with GD (36).
Immune system abnormalities in GD are represented by 
TSH-R-reactive B cells, which escape deletion and eventually pre-
sent this thyroid autoantigen to T cells. When activated, T cells 
secrete several pro-inflammatory cytokines and chemokines 
(37, 38). Hence both B  cells and T  cells play a central role in 
perpetuating the autoimmune cascade in GD (11, 37).
AiTDs AND ALeMTUZUMAB
Among several autoimmune conditions, which have been 
reported to occur following Alemtuzumab treatment, the 
present review will focus on GD, the most frequently observed 
one. The occurrence of GD in Alemtuzumab-treated patients 
with secondary progressive MS was first described in 1999 
(39). In this early report, a third of MS patients (9/27) receiving 
the anti-CD52 monoclonal Ab developed GD, with circulat-
ing TRAb and hyperthyroidism (39). Besides being the first 
description, the study by Coles et  al. is of great interest, as it 
clearly shows that GD (and its humoral marker, TRAb) is the 
most prevalent form of AITD occurring in MS patients treated 
with Alemtuzumab (39). By contrast, in MS patients, treated 
with other immunomodulatory therapies (i.e., IFN-β), the most 
prevalent side effect is represented by euthyroid or hypothyroid 
autoimmune thyroiditis (26, 27, 40). Thus, a first crucial dif-
ference between IFN-β and Alemtuzumab was already evident: 
they elicited different autoimmune reactions driving the onset 
of Hashimoto’s thyroiditis and GD, respectively.
Subsequent studies, investigating the efficacy and safety of 
Alemtuzumab therapy in patients with RRMS, confirmed GD 
as the main autoimmune sequela of this immunomodulatory 
treatment. In 2008, Coles et  al. published a phase 2 clinical 
trial (CAMMS223) in which 334 patients with RRMS were 
randomized to receive either IFN-β-1a three times/week or 
annual cycles of Alemtuzumab (either 12 or 24  mg/day) for 
3 years (41). Among other (rare) autoimmune side effects, such 
as trombocytopenic purpura and glomerulonephritis due to 
autoantibodies binding the glomerular basal membrane, they 
reported a significantly higher rate of thyroid autoimmunity in 
patients treated with Alemtuzumab as opposed to those receiv-
ing IFN-β-1a (22.7 versus 2.8%, respectively) (41). In 2012, two 
phase-3 trials also reported the occurrence of mild to moderate 
thyroid dysfunction in nearly 18% of RRMS patients treated with 
Alemtuzumab (1, 2).
The early series of patients included in the CAMMS223 study 
(2) was further investigated with the specific aim of evaluating 
thyroid side effects of Alemtuzumab therapy (42). Daniels 
et  al. prolonged the surveillance period of these patients up to 
a median time of 57.3 months and a maximum of 80.6 months 
(42). They confirmed that thyroid dysfunctions more frequently 
occurred in patients treated with Alemtuzumab as compared to 
those receiving IFN-β-1a. In particular, 34% of patients treated 
with Alemtuzumab developed thyroid dysfunctions (39% receiv-
ing 12 mg and 29% receiving 24 mg) as compared with a 6.5% 
rate in those treated with IFN-β-1a. As shown in Table  1, in 
the Alemtuzumab treatment group, GD was the most prevalent 
condition, being experienced by nearly 23% of patients (42). 
Hypothyroidism was observed in 7.4% patients and destructive 
thyroiditis with thyrotoxicosis in 4.2% of patients (42).
Some clinical peculiarities of these patients are worth 
noting. The first episode of thyroid dysfunction was observed 
starting from the first year after Alemtuzumab administration. 
Afterward, the episodes’ prevalence progressively increased 
each year for the first 3  years (from 4.6 to 16.1%) with a 
subsequent decrease in the following 4  years (from 11.3 to 
5.9%). There was a higher than expected prevalence (52.7%) 
of patients in whom Graves’ hyperthyroidism (either overt or 
subclinical) was spontaneously reverted to hypothyroidism 
(either overt or subclinical) (Table 2). An unusual frequency of 
patients converting from hyperthyroidism to hypothyroidism 
and vice versa was also observed. Importantly, the conversion 
from hyperthyroidism to hypothyroidism was accompanied by 
the occurrence of TRAb in nearly 77% of patients (Table 3). 
This observation strongly suggests that the conversion from 
hyperthyroidism to hypothyroidism was likely due to a shift 
in the ratio between stimulating and blocking TRAbs. In the 
routine endocrine practice of sporadic GD, the transition from 
hyperthyroidism to hypothyroidism is a unusual event, which 
is mainly observed several years after a successful course of 
antithyroid drugs and is rarely accompanied by TRAb positiv-
ity (43). Taken together, these data indicate that the immune 
reconstitution occurring after Alemtuzumab treatment is 
TABLe 5 | Studies reporting Alemtuzumab-related thyroid dysfunction.
Reference No. of  
patients
No. of patients 
who developed 
thyroid 
dysfunctions
Thyroid function
Coles et al. (39) 27 9/27 (33%) Hyperthyroidism: 9 (33%)a
Coles et al. (41) 216a 49/216 (22.7%) Hyperthyroidism: 32 (14.8%)
Hypothyroidism: 15 (6.9%)
Coles et al. (2) 596 100/596 (16.7%) Hyperthyroidism: 28 (4.7%)
Hypothyroidism: 31 (5.2%)
Cohen et al. (1) 376 68/376 (18%) Hyperthyroidism: 28 (7%)
Hypothyroidism: 18 (5%)
Tuohy et al. (45) 87 35/87 (41%) Hyperthyroidism: 22 (25.3%)
Hypothyroidism: 12 (13.8%)
aOne patient developed hypothyroidism before shifting to hyperthyroidism.
TABLe 4 | TPOAb and thyroid dysfunction during Alemtuzumab treatment.
Patients and TPOAb (%)
Patients with postive TPOAb at baseline 8.0
Patients with negative TPOAb at baseline who develop thyroid 
dysfunction
31.0
Patients with postive TPOAb at baseline who develop thyroid 
dysfunction
69.0
•	 Graves’ hyperthyroidism
•	 Hypothyroidism
•	 Destructive thyroiditis
•	 Euthyroidism
31.2
25.0
12.5
31.2
Positive TPOAb at the time of thyroid dysfunction 69.8
•	 Positive TPOAb at baseline
•	 De novo positive TPOAb
•	 Persistently positive TPOAb
15.1
54.8
30.1
De novo positive TPOAb without thyroid dysfunction 10.5
Data elaborated from Daniels et al. (42).
TABLe 3 | TSH-receptor antibodies (TRAb) and thyroid dysfunction during 
Alemtuzumab treatment.
Patients and TRAb (%)
Positive TRAb at baseline 0.0
De novo positive TRAb 38.0
Thyroid dysfunction and TRAb status
•	 Positive TRAb 70.0
Hyperthyroidism and TRAb status
•	 Positive TRAb 84.7
Graves’ disease and TRAb status
•	 Positive TRAb 100
Hypothyroidism and TRAb status
•	 Positive TRAb 76.7
Data elaborated from Daniels et al. (42).
TABLe 2 | Treatment and outcome of Graves’ disease developing after 
Alemtuzumab therapy.
(%)
Therapy of overt hyperthyroidism in Graves’ disease
•	 Antithyroid drugs alone
•	 Antithyroid drugs + radiometabolic therapy (131-I)
•	 Radiometabolic therapy alone (131-I)
•	 Surgery (total thyroidectomy)
40.1
12.2
6.1
4.0
Outcome of overt hyperthyroidism in Graves’ disease
•	 Spontaneous resolution with:
– Euthyroidism
– Hypothyroidism
36.7
20.4
16.3
Therapy of subclinical hyperthyroidism
•	 Antithyroid drugs alone 36.4
Outcome of subclinical hyperthyroidism in Graves’ disease 63.6
•	 Spontaneous resolution
•	 Subclinical hypothyroidism
•	 Overt hypothyroidism
•	 Unknown
18.2
18.2
18.2
9.1
Data elaborated from Daniels et al. (42).
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mainly humoral, being directed to the TSH-R as a major 
auto antigen.
Risk factors for the development of Alemtuzumab-induced 
GD were a family history of thyroid diseases, female sex, younger 
age, smoking habit, lower administered dose of the monoclonal 
Ab, and pretretment postivity for thyroid peroxidase (TPO) 
antibody (Ab). However, TPOAb had a minor relevance as a 
risk factor, due to the low frequency of pre-teratment positive 
results for this autoimmune marker (Table  4). Daniels et  al. 
found that only 16/206 (8%) patients were positive for TPOAb 
at baseline. Among them, the prevalence of thyroid dysfunction 
after Alentuzumab treatment was 69%, a much higher rate than 
the 31% one observed in patients who were TPOAb negative at 
baseline (44). However, the majority (85%) of patients developing 
a thyroid disorder were negative for TPOAb before Alentuzumab 
treatment. Therefore, regardless of the pretreatment TPOAb sta-
tus, patients may develop a thyroid disfunction and should have 
thyroid function tests performed periodically (41).
The remission rate of Alemtuzumab-induced Graves’ 
hyper thyroidism, either spontaneous or after antithyroid drug 
treatment (Table 2), was also higher (78%) than what commonly 
observed in the sporadic form of the disease (32).
In a futher observational cohort study, Tuohy et  al. (45) 
re-evaluated 87 patients with RRMS who had been treated with 
Alemtuzumab in investigator-led studies in Cambridge from 
1999 to 2012. This series included 67 patients of the CAMMS224 
trial (18) and 20 of the SM3 trial (46). Among the 86 patients 
who completed the study, 35 (41%) developed a thyroid dys-
function, which was diagnosed as Graves’ hyperthyroidism in 22 
(63%) and as hypothyroidism with positive tests for TPOAb in 
12 (34%) of them. The main limitation of this study is that TRAb 
were not measured. At the present, large series studies aimed 
at evaluating the occurrence of thyroid dysfunctions in RRMS 
patients treated with Alemtuzumab reported a prevalence rang-
ing from 16.7 to 41% (Table 5). The remaining published studies 
on the occurrence of GD in Alemtuzumab-treated patients 
mainly consist of single case or small series reports, which 
are summarized in Table  6. In the majority of these reports, 
patients developing AITD were taking Alemtuzumab for a 
RRMS (47–50). However, reconstitution GD was also described 
in patients receiving Alemtuzumab for other clinical conditions. 
The development of Graves’ hyperthyroidism was described by 
TABLe 6 | Case reports of patients developing autoimmune thyroid diseases following Alemtuzumab administration.
Reference Case(s) Disease Thyroid function Thyroid Ab Treatment
Kirk et al. (52) 1 (F) Kidney  
transplantation
Hyperthyroidism TSH-RAb+ Carbimazole
TgAb n/a
TPOAb n/a
Aranha et al. (47) 1 (F) Multiple  
sclerosis (MS)
Hyperthyroidism TSH-RAb+
TgAb+
TPOAb+
Carbimazole,  
thyroidectomy
2 (F) MS Hyperthyroidism TSH-RAb+
TgAb−
TPOAb−
Carbimazole,  
thyroidectomy
3 (F) MS Hyperthyroidism,  
then hypothyroidism
TSH-RAb+
TgAb n/a
TPOAb n/a
Carbimazole,  
then levothyroxine
4 (F) MS Hyperthyroidism TSH-RAb+
TgAb+
TPOAb+
Carbimazole
Tsourdi et al. (48) 1 (M) MS Hyperthyroidism TSH-RAb+
TgAb+
TPOAb+
Thiamazole
2 (F) MS Hyperthyroidism TSH-RAb+
TgAb+
TPOAb+
Thiamazole,  
thyroidectomy
3 (F) MS Hyperthyroidism TSH-RAb+
TgAb+
TPOAb–
Thiamazole,  
thyroidectomy
4 (M) MS Hyperthyroidism TSH-RAb+
TgAb−
TPOAb+
Thiamazole,  
thyroidectomy
5 (F) MS Mild hyperthyroidism TSH-RAb+
TgAb+
TPOAb+
No therapy
Williams et al. (53) 1 (M) Hematopoietic  
cell transplantation
Hypothyroidism TSH-RAb n/a
TgAb+
TPOAb+
Levothyroxine
2 (M) Hematopoietic  
cell transplantation
Hyperthyroidism TSH-RAb−
TgAb+
TPOAb+
Methimazole
3 (M) Hematopoietic  
cell transplantation
Hyperthyroidism TSH-RAb−
TgAb+
TPOAb+
Methimazole
Mahzari et al. (49) 1 (M) MS Hyperthyroidism,  
then hypothyroidism
TSH-RAb n/a
TgAb n/a
TPOAb+
Propylthiouracil,  
then levothyroxine
2 (F) MS Hyperthyroidism,  
then hypothyroidism
TSH-RAb n/a
TgAb n/a
TPOAb+
No therapy,  
then levothyroxine
3 (F) MS Hyperthyroidism TSH-RAb n/a
TgAb n/a
TPOAb+
Methimazole
4 (F) MS Mild hyperthyroidism,  
then hypothyroidism
TSH-RAb n/a
TgAb n/a
TPOAb+
No therapy,  
then levothyroxine
Obermann et al. (50) 1 (M) MS Hyperthyroidism TSH-RAb+
TgAb+
TPOAb+
Carbimazole
2 (M) MS Subclinical  
hypothyroidism
TSH-RAb−
TgAb+
TPOAb+
No therapy
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Walsh et al. in 11% of patients treated with Alemtuzumab for 
vasculitis (51). Other reports include (i) a young kidney trans-
plant recipient who developed GD 4 years after Alemtuzumab 
treatment (52) and (ii) three pediatric cases of thyroid autoim-
mune diseases in patients receiving Alem tuzumab after hemat-
opoietic cell transplantation (53).
At variance with all the above described studies, the deve-
lopment of immune reconstition GD was not observed in a 
large series of patients with rheumatoid arthritis treated with 
Alemtuzumab (54). These negative findings support the view 
that patients with MS bear a higher intrinsic risk for the devel-
opment of Alemtuzumab-related thyroid dysfunctions. Further 
support to the above statement stems from the notion that while 
Alemtuzumab is increasingly prescribed in chronic lymphocytic 
leukemia, no case of Graves’ hyperthyroidism has been reported 
in these patients.
FiNAL ReMARKS
Reconstitution GD may occur during the recovery phase of 
Alemtuzumab-induced CD52 cells depletion. Because reconsti-
tution autoimmunity is more frequently related to autoantibody-
mediated diseases rather than to destructive, Th1-mediated 
disorders (i.e., Hashimoto’s thyroiditis), it is not surprising that 
GD is the most commonly reported side effects of Alemtuzumab 
treatment.
The reason why, as compared with patients bearing other clini-
cal conditions, those with MS carry a higher risk for the develop-
ment of GD after Alemtuzumab treatment remains unknown. 
Genetic factors and/or specific clinical aspects of MS, such as the 
cytokine/chemokine milieu and/or the RR clinical course, might 
play a role, but there is still no definite proof at this regard.
From a clinical point of view, there are peculiar aspects of 
Alemtuzumab-induced GD. First, hyperthyroid patients have an 
unusualy high rate of spontaneous shift to hypothyroidism. This 
shift is supposed to result from a change from stimulating to block-
ing TRAb. Second, the remission rate of Graves’ hyperthyroidism, 
both spontaneous and after antithyroid drugs, is unexpectedly 
high, suggesting a less aggressive disease (14). This observation 
implies that antithyroid drugs should be the first-line treatment 
in patients with Alemtuzumab-induced Graves’ hyperthyroidism.
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